Inhibrx, Inc. (NASDAQ:INBX) Sees Large Drop in Short Interest

Inhibrx, Inc. (NASDAQ:INBX - Get Free Report) was the recipient of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 955,400 shares, a decline of 19.7% from the February 28th total of 1,190,000 shares. Currently, 9.6% of the company's shares are short sold. Based on an average daily volume of 91,300 shares, the short-interest ratio is currently 10.5 days.

Inhibrx Stock Performance

Shares of Inhibrx stock traded up $0.01 during trading on Friday, hitting $13.34. 270,761 shares of the stock traded hands, compared to its average volume of 215,338. The stock's fifty day simple moving average is $13.39 and its 200 day simple moving average is $14.53. Inhibrx has a 52-week low of $10.80 and a 52-week high of $35.42.

Inhibrx (NASDAQ:INBX - Get Free Report) last posted its earnings results on Monday, March 17th. The company reported ($3.09) EPS for the quarter, missing analysts' consensus estimates of ($2.88) by ($0.21). The business had revenue of $0.10 million for the quarter. On average, equities research analysts expect that Inhibrx will post 104.88 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, JMP Securities reissued a "market perform" rating on shares of Inhibrx in a research note on Wednesday, January 22nd.

Remove Ads

Institutional Trading of Inhibrx

Hedge funds have recently bought and sold shares of the stock. PNC Financial Services Group Inc. bought a new position in shares of Inhibrx in the 4th quarter worth $28,000. Natixis purchased a new position in Inhibrx in the fourth quarter valued at about $31,000. China Universal Asset Management Co. Ltd. bought a new position in Inhibrx in the fourth quarter worth about $47,000. New York State Common Retirement Fund purchased a new stake in shares of Inhibrx during the fourth quarter valued at about $53,000. Finally, State of Wyoming bought a new stake in shares of Inhibrx in the 4th quarter valued at about $83,000. Hedge funds and other institutional investors own 82.46% of the company's stock.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.